Status:
COMPLETED
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
Lead Sponsor:
University of Michigan
Conditions:
Liver Tumor
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (Eovist) or intravenous gadobenate dimeglumine (MultiHance).
Detailed Description
Contrast-enhanced hepatic MRI is an accepted method for detecting and characterizing liver lesions. Liver lesion characterization is fundamental for patient management, because lesions that meet speci...
Eligibility Criteria
Inclusion
- Patients 18 years old and older
- Patients scheduled for MRI examination at the University of Michigan hospital
- Patients receiving either MultiHance or Eovist contrast agents during their clinical MRI examination
Exclusion
- Patients under 18 years of age
- Patients who will not receive MultiHance or Eovist as part of their clinical MRI examination
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT02226666
Start Date
August 1 2013
End Date
December 1 2015
Last Update
January 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Hospital
Ann Arbor, Michigan, United States, 48109